HCW Biologics Inc. (HCWB) stock
Close on Nov 11, 2026Market cap $1.58MP/E –Yield –
HCW Biologics Inc. grew revenue 700.2% to $6.66M over the twelve months to Jun 30, 2026. Free cash flow was -$13.39M. At the latest close the market valued the company at $1.58M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.58M
- P/E ratio
- –
- Price to sales
- 0.24
- Price to book
- 0.21
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $6.66M
- Net income
- -$5.58M
- EPS, diluted
- -$28.41
- Free cash flow
- -$13.39M
- Book value per share
- $5.59
- Diluted shares
- 1M
Trading
- Next earnings
- Nov 13, 2026 (estimated, after the close)
- Previous close
- $0.94
- Open
- $0.95
- Day's range
- $0.86 – $1.00
- Volume
- 35,992
- Average volume (20 days)
- 51,659
- Beta (5 years)
- 0.76
- 52-week range
- $0.86 – $23.94
- RSI (14 days)
- 24.5
- Volatility (1 year)
- 330.7%
- Relative volume
- 0.12×
- WACC
- 7.0%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | HCWB | S&P 500 | Difference | HCWB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -46.3% | -2.4% | −43.8 pts | ||
| 3 months | -72.9% | -1.2% | −71.7 pts | ||
| Year to date | -85.2% | +12.3% | −97.5 pts | ||
| 1 year | -94.9% | +12.4% | −107.4 pts | ||
| 3 years | -99.7% | +78.8% | −178.6 pts | -86.3% | +21.4% |
| 5 years | -99.9% | +75.2% | −175.0 pts | -73.8% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases HCW Biologics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Update
- Update
About HCW Biologics
Pharmaceutical Preparations
HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel fusion immunotherapeutics to treat conditions driven by chronic inflammation. Its pipeline targets autoimmune and proinflammatory diseases, cancer, and senescence-associated dysplasia. The company designs its product candidates using two proprietary platforms, TOBI and TRBC. Its lead clinical candidate, HCW9302, is an injectable fusion protein complex being evaluated for alopecia areata. HCW Biologics also develops commercial-ready reagent molecules, including HCW9201 and HCW9206, which serve biopharmaceutical customers producing CAR-T and natural killer cell therapies for cancer and infectious diseases.
Company profile, executives and historyHCW Biologics stock: common questions
What is HCW Biologics's stock price?
HCWB closed at $0.86 on Nov 11, 2026, down 8.51% on the day. Over the past 52 weeks it traded between $0.86 and $23.94.
What is HCW Biologics's market cap?
HCW Biologics was worth $1.58M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is HCWB's P/E ratio?
HCW Biologics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$28.41), so it has no meaningful P/E ratio.
How much revenue does HCW Biologics make?
HCW Biologics reported revenue of $6.66M for the twelve months to Jun 30, 2026, up 700.2% from a year earlier.
Does HCW Biologics pay a dividend?
No. HCW Biologics has not paid a cash dividend over the last twelve months.
When does HCW Biologics report earnings next?
HCW Biologics is expected to report Q3 FY2026 results on Nov 13, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has HCWB stock performed over the past year?
Including dividends, HCWB returned -94.9% over the past year, against +12.4% for the S&P 500.
How many HCWB shares are sold short?
0M shares were sold short at the latest FINRA report, 4.12% of the float, or 1.0 days of average trading volume.
Who are HCW Biologics's competitors?
Companies most similar to HCW Biologics by business, industry and size include EVMN, ACRS, BOLT, TVRD, ROIV.
See a number that looks wrong?